Treatment(s) already received-Radiation - Page 8 of 9 Posts on Medivizor
Navigation Menu

Treatment(s) already received-Radiation Posts on Medivizor

Metastatic colorectal cancer: the benefit of combining cetuximab with chemotherapy

Metastatic colorectal cancer: the benefit of combining cetuximab with chemotherapy

Posted by on Mar 5, 2013 in Colorectal cancer | 0 comments

In a nutshell The present study investigated if patients with spread colorectal cancer that have mutations in the KRAS gene benefit from Cetuximab treatment. Some background Cancer that originates in the colon or rectum (parts of the intestine) is called colorectal cancer (CRC). If the cancer has spread from its original location, beyond the...

Read More

The association between insulin blood levels and risk of death in breast cancer patients

Posted by on Feb 28, 2013 in Breast cancer | 0 comments

In a nutshell The present study evaluated the relationship between high insulin levels in the blood stream and the risk of cancer-related mortality. Its authors report that women with higher-than-normal insulin levels are at higher risk of death due to breast cancer. Some background Breast cancer has been shown to be more common in people who...

Read More

Personalizing breast cancer treatment based on the genetic “finger-print” of the tumor

Personalizing breast cancer treatment based on the genetic “finger-print” of the tumor

Posted by on Feb 25, 2013 in Breast cancer | 0 comments

This article discusses how tests such as the Oncotype DX or Mammaprint can be used to design individual treatment plans for patients with breast cancer. Patients with stage I and stage II breast cancer are treated similarly. Following surgical removal of a breast tumor, systemic (body-wide) treatment is often used.  This secondary treatment is...

Read More

Benefits of postoperative chemotherapy vary according to breast cancer type

Benefits of postoperative chemotherapy vary according to breast cancer type

Posted by on Feb 25, 2013 in Breast cancer | 0 comments

In a nutshell This study questioned the benefit of adding chemotherapy to postoperative hormonal treatment in the case of lobular breast cancer. Their findings were that chemotherapy seems to offer no additional beneficial effects in women with lobular breast cancer receiving hormonal therapy. Some background There are two main types of breast...

Read More

Postoperative radiotherapy prevents breast cancer recurrence and prolongs survival

Posted by on Feb 25, 2013 in Breast cancer | 0 comments

In a nutshell This study evaluated if strategies to prevent cancer recurrence are associated with prolonged survival 15 years after treatment. Their main findings were that postoperative radiation managed to prevent cancer recurrence and was associated with higher rates of long-term survival. Some background Early breast cancer is often treated...

Read More

Standard Chemotherapy versus Capecitabine (Xeloda) in Older Women with Early-Stage Breast Cancer

Standard Chemotherapy versus Capecitabine (Xeloda) in Older Women with Early-Stage Breast Cancer

Posted by on Feb 24, 2013 in Breast cancer | 0 comments

In a nutshell This trial compared standard chemotherapy regimens and Capecitabine (Xeloda) in women over 65 years old. The main outcome was that standard chemotherapy worked better in this age group. Some background Capecitabine is generally used in breast cancer resistant to other chemotherapy. It is also the first approved treatment that can be...

Read More

Does Tamoxifen reduce the risk of cancer in a second breast in BRCA1 and BRCA2 carriers?

Does Tamoxifen reduce the risk of cancer in a second breast in BRCA1 and BRCA2 carriers?

Posted by on Feb 24, 2013 in Breast cancer | 0 comments

In a nutshell The risk of breast cancer is high (~80%) in women who inherit a damaged (mutated) gene called BRCA1 or BRCA 2 (‘BRCA carriers’). Following the first diagnosis, their risk of developing another tumor in the second breast within 10 years is 30%. Some background Some types of breast cancer need estrogen (female sex...

Read More

Sexual, urinary, hormonal and bowel function – a comparison between prostate cancer survivors and noncancer men

Sexual, urinary, hormonal and bowel function – a comparison between prostate cancer survivors and noncancer men

Posted by on Feb 24, 2013 in Prostate cancer | 0 comments

In a nutshell The present study compared survivors of prostate cancer (PC) to patients of similar sexes and ages that have not had prostate cancer (non-cancer controls) based on the effects of prior treatments and treatment options on sexual, urinary, bowel and hormone functions. The main finding was that PC survivors had poorer sexual and urinary...

Read More

Prostatectomy and radiation effects on urinary, bowel and erectile dysfuntion 2, 5 and 15 years after prostate cancer diagnosis

Prostatectomy and radiation effects on urinary, bowel and erectile dysfuntion 2, 5 and 15 years after prostate cancer diagnosis

Posted by on Feb 24, 2013 in Prostate cancer | 0 comments

In a nutshell This paper evaluated the long-term influence of prostate cancer treatment with prostatectomy or radiotherapy on urinary, bowel and sexual function. Prostatectomy was associated with a higher rate of urinary and erectile dysfunction, whereas radiotherapy caused more frequent bowel urgency at 2 and 5 years after diagnosis. Some background...

Read More